These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 18188524

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, Moon KC, Koh JK.
    Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.
    McLellan B, Kerr H.
    Dermatol Ther; 2011 Nov; 24(4):396-400. PubMed ID: 21910797
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
    Alexandrescu DT, McClure R, Farzanmehr H, Dasanu CA.
    J Clin Oncol; 2008 Aug 20; 26(24):4047-8. PubMed ID: 18711201
    [No Abstract] [Full Text] [Related]

  • 8. [Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib].
    Wollenberg A, Staehler M, Eames T.
    Hautarzt; 2010 Aug 20; 61(8):662-7. PubMed ID: 20631979
    [Abstract] [Full Text] [Related]

  • 9. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB, Coleman TA, Davis CH, Carbonell CE, Davis WB.
    Am J Clin Oncol; 2010 Jun 20; 33(3):217-20. PubMed ID: 19745694
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as a paradigm.
    Sulkes A.
    Isr Med Assoc J; 2010 Oct 20; 12(10):628-32. PubMed ID: 21090521
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Two new drugs for renal cell carcinoma.
    Med Lett Drugs Ther; 2007 Feb 26; 49(1255):18-20. PubMed ID: 17325624
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Renal toxicity of targeted therapies.
    Kelly RJ, Billemont B, Rixe O.
    Target Oncol; 2009 Apr 26; 4(2):121-33. PubMed ID: 19421832
    [Abstract] [Full Text] [Related]

  • 20. Reversible cardiomyopathy associated with sunitinib and sorafenib.
    Uraizee I, Cheng S, Moslehi J.
    N Engl J Med; 2011 Oct 27; 365(17):1649-50. PubMed ID: 22030001
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.